{
    "2019-07-05": [
        [
            {
                "time": "",
                "original_text": "医药行业2019年上半年疫苗批签发总结：行业正逐步恢复，核心重磅品种持续放量【西南医药朱国广陈铁林团队】",
                "features": {
                    "keywords": [
                        "医药行业",
                        "疫苗",
                        "批签发",
                        "逐步恢复",
                        "核心重磅品种",
                        "持续放量"
                    ],
                    "sentiment_score": 0.75,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "48股获券商买入评级 利民股份目标涨幅达78.57%",
                "features": {
                    "keywords": [
                        "48股",
                        "券商买入评级",
                        "利民股份",
                        "目标涨幅",
                        "78.57%"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "股票"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}